Health Condition 1: null- Patients having head and neck cancers who are unsuitable for cisplatin based chemoradiation
Conditions
Interventions
Intervention1: Radical or Adjuvant radiation with chemotherapy: Radical ( 70 Gy over 7 weeks) or Adjuvant Radiation ( 60 Gy over 6 weeks) with chemothearpy weekly docetaxel 15 mg/m2 maximum 7 cycl
Sponsors
Tata Memorial Hospital
Eligibility
Inclusion criteria
Inclusion criteria: 1. Participants must have a histologically confirmed stage III-IV squamous cell cancers of the head and neck region. 2. Participants must warrant CTRT must warrant at least one of the following a. Radical setting : stage III-IV head and neck cancer b. Adjuvant setting : Stage III-IV head and neck cancer postoperative with one of the below mentioned feature on pathology specimen i. Extracapsular extension ii. Margin positive iii. Close margin ( cut margin 0.5 mm or below) 3. Participants must have malignancy arising from one of the following sites oral cavity, pharynx ( inclusive of oropharynx, hypopharynx) or larynx ( inclusive of supraglottis, glottis and subglottis) or CUP ( carcinoma unknown primary) with neck nodes 4. Unsuitable for cisplatin due to at least anyone of the following reason a. Performance status ECOG (Eastern Cooperative Oncology Group) score of grade 2 b. Organ dysfunction of grade 2 or higher based on the NCI CTC (National Cancer Institute Common Toxicity Criteria) version 4.0 , such as hearing loss and tinnitus and neurologic disorders c. Hypersensitivity to Cisplatin d. Calculated creatinine clearance (CCR) value of e. Borderline organ function or comorbidities precluding use of cisplatin f. Weight loss : > 10% of baseline body weight in preceding 6 months g. Nutritional status : Malnourished status as defined by BMI 16 KG/m2 h. Concomitant use of nephrotoxic drugs required for concurrent medical condition 5. Age : Any age above 18 years. No maximum age. 6. ECOG performance status 7. Participants must have normal organ and marrow function as defined below: a. Leukocytes >=3,000/mcL b. Platelets >=100,000/mcL c. Total bilirubin d. AST(SGOT)/ALT(SGPT) e. Calculated Creatinine clearance > 30 ml/min 8. The effects of docetaxel chemotherapy on the developing human fetus are teratogenic. Hence women of childbearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 6 months after completion of protocol. 9. Both men and women of all races and ethnic groups are eligible for this trial. 10. Willing and able to comply with all study requirements 11. Ability to understand and the willingness to sign a written informed consent document
Exclusion criteria
Exclusion criteria: 1. Participants who are receiving any other investigational agents. 2. Primary sites of malignancy major salivary gland or nasopharynx or skin 3. Patients with QTc prolongation defined as QTc interval greater than 480 ms in view of risk of sudden cardiac death associated with use of antiemetics. 4. History of allergic reactions attributed to compounds of similar chemical or biologic composition to any agents used in study. 5. Uncontrolled intercurrent illness including, but not limited to tuberculosis, diabetes, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, renal failure (on dialysis), active gastrointestinal bleeding, cerebrovascular accidents, inflammatory bowel disease, known hyperkalemia ( CTCAE version 4.02 grade 3 or above which is persistent over 1 week) or psychiatric illness/social situations that would limit compliance with study requirements. 6. Pregnant women and breastfeeding women are excluded from this study because docetaxel has the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants. These potential risks may also apply to other agents used in this study. 7. HIV-positive, Active Hepatitis B and Active Hepatitis C seropositive patients are excluded from this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1.Overall survival Timepoint: 1. 2 Years | — |
Secondary
| Measure | Time frame |
|---|---|
| 1.Disease Free survival 2.Quality of life 3.ToxicityTimepoint: 1.2 Years 2.At baseline, 6 months, 12 months and at 24 months 3.Between the 2 arms during any period of chemotherapy | — |
Countries
India
Contacts
Public ContactDr Vijay Patil
Tata Memorial Hospital
Outcome results
None listed